Loading...
Market
What will be the regulatory outcome for Pfizer's Oxbryta withdrawal by December 31, 2024?
2
Resolution / Starting Odds
No action taken • 25%
Warning issued • 25%
Fine imposed • 25%
Other sanctions • 25%
Official announcements from regulatory bodies such as the FDA or EMA
Story
Pfizer ($PFE) Withdraws Sickle Cell Drug Oxbryta from Global Markets
Sep 25, 2024, 09:07 PM
Pfizer Inc. ($PFE) announced on Wednesday that it is voluntarily withdrawing all lots of its sickle cell disease treatment Oxbryta (voxelotor) from worldwide markets. The decision comes after data indicated an imbalance in vaso-occlusive crises and fatal events associated with the drug. This withdrawal marks a significant setback for Pfizer, following its $5.4 billion acquisition of Global Blood Therapeutics, the original developer of Oxbryta. The company stated that the overall benefit of Oxbryta no longer outweighs the risks involved.
View original story
Similar markets
Introduce a new sickle cell treatment • 25%
Acquire another company with a sickle cell treatment • 25%
Exit the sickle cell treatment market • 25%
No major action • 25%
Yes • 50%
No • 50%
Decrease by more than 5% • 25%
Decrease by 1-5% • 25%
No significant change • 25%
Increase • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved • 33%
Rejected • 33%
Request for more data • 34%
Yes • 50%
No • 50%
Approved • 25%
Rejected • 25%
Request for additional trials • 25%
Request for additional data • 25%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%